CYP2C19 Poor Metabolizer Status and Antidepressant Treatment

Understanding CYP2C19 Poor Metabolizer Status

Poor metabolizers have significantly reduced metabolic clearance of parent SSRIs, resulting in longer drug half-life and elevated plasma concentrations, with lower concentrations of active metabolites 1, 2
The American College of Medical Genetics and Genomics recommends considering CYP2C19 genotyping before starting certain medications, such as citalopram and escitalopram, although routine genetic testing is not currently recommended for initial SSRI prescribing 1, 3, 2

For known CYP2C19 poor metabolizers, start at 50% of standard initial dose for citalopram/escitalopram and titrate more slowly than usual, monitoring for adverse effects, with consideration of therapeutic drug monitoring 1, 2
Common adverse effects in CYP2C19 poor metabolizers include nausea and gastrointestinal symptoms, which are more prevalent in this population 1, 3, 2
The EGAPP Working Group found insufficient evidence to recommend routine CYP450 genetic testing before starting SSRI treatment, but testing may be considered after treatment failure or intolerable side effects 1, 3, 2

Most clinical validity studies rated quality level 3-4 out of 5 by Oxford Centre criteria, with single-dose pharmacokinetic studies in healthy volunteers showing clear genotype effects, but steady-state studies in patients showing mixed results 1, 3, 2
Only five studies evaluated genotype-clinical response relationships, with inconsistent findings, highlighting the need for further research in this area 1, 3, 2

CYP2C19 genotyping before starting sertraline is classified as "potentially beneficial" but not mandatory, and may be considered in patients with treatment failure, as CYP2C19 ultra metabolizers have higher prevalence among SSRI non-responders 4
The EGAPP Working Group found insufficient evidence to recommend routine CYP450 genetic testing for patients starting SSRI treatment, according to the Evaluation of Genomic Applications in Practice and Prevention Working Group 5

Therapeutic drug monitoring of sertraline plasma concentrations is not routinely recommended, as correlations between plasma levels and therapeutic effects are sparse, with a therapeutic range of 10-50 ng/mL 6